BioCardia Announces FDA Completes Review of Proposed Adaptive Statistical Analysis Design for Ongoing CardiAMP Cell Therapy in Heart Failure Pivotal Study
June 20, 2023 17:14 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study
May 23, 2023 07:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases...
BioCardia Reports First Quarter 2023 Business Highlights and Financial Results
May 10, 2023 16:05 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications
May 09, 2023 07:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available
April 28, 2023 07:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
Clinical trial to test wearable device as treatment for chronic pain, opioid withdrawal
January 17, 2023 12:47 ET
|
Spark Biomedical
GALVESTON, Texas, Jan. 17, 2023 (GLOBE NEWSWIRE) -- A multi-year clinical trial at the University of Texas Medical Branch (UTMB) and Medical University of South Carolina (MUSC) will examine the use...
Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada
February 17, 2022 07:12 ET
|
Resverlogix Corp
CALGARY, Alberta, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced that the first Brazilian site has been initiated for its Phase 2b study to evaluate...
Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment
January 18, 2022 07:15 ET
|
Resverlogix Corp
CALGARY, Alberta, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today that enrollment and dosing of patients has commenced in a Phase 2b study...
CENTOGENE Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases
November 04, 2021 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Drug Apabetalone
November 01, 2021 08:30 ET
|
Resverlogix Corp
CALGARY, Alberta, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX), a world leader in epigenetics or gene regulation, is pleased to announce today...